is the first alternative we came up with. As no other competitors are in the vet blood substitutes market, Biopure will definitely have the first-mover advantage as long as they launch it in a timely manner/fast enough. Also any other competitors won’t be able to jeopardize the Oxyglobin’s profitability as it takes about 2 to 5 years for them to obtain FDA-approval. Assuming that Biopure decides to launch it, they also have to consider how much they are gonna charge for the product. In the first
Words: 483 - Pages: 2
To: Carl Rausch, President and CEO, Biopure From: Team 1 Subject: Launch Strategies for Oxyglobin Team 1 strongly recommends the launch of Oxyglobin in the veterinary market as soon as possible. In order to make this launch as successful as possible, Team 1 recommends: * Launching Oxyglobin from a fully-owned subsidiary of Biopure * Establishing an initial launch price of $xxx * Focus the supply chain on Critical Care Veterinary services * Establish a direct to consumer advertising
Words: 351 - Pages: 2
Biopure Corporation: Case Write-Up Problem Definition In February 1998 Biopure Corporation faced a difficult decision regarding the launch of its newly developed “blood substitute” products. Biopure had developed “Hemopure”, a blood substitute for humans, and an ancillary product “Oxyglobin” for the veterinary market1. Hemopure was still in the process of gaining Federal Drug Administration (FDA) approval , while Oxyglobin had already been approved and was ready to be launched1. FDA approval was
Words: 1372 - Pages: 6
Case Write-up #4: Biopure Issues: The main issue for Biopure corporation was the strategic decision on when to introduce Oxyglobin. What should be the launch strategy for Oxyglobin that ensures that the potential of Hemopure would not be affected? SWOT analysis & Reommendation: S: Oxyglobin is the first blood substitute that has received full government approval. The FDA approval would be a time consuming process, the company will be the first player to enter the market and gain first entry
Words: 420 - Pages: 2
Areya Popal Case Analysis: Biopure Corporation Background: Biopure Corporation is a company that produces artificial “blood substitutes” that are used in humans and animals. Currently their product for animals, “Oxyglobin”, has passed FDA approval and can begin selling but the human product “Hemopure” is still in phase 3 trials. The problem presenting itself for Biopure is whether to release Oxyglobin now or later, with Hemopure. This is because they feel that it will bring up questions as to why
Words: 472 - Pages: 2
Biopure Corporation: A Case Study Biopure Corporation specializes in blood substitutes for transfusion patients, both in the veterinary market and the human market. However, in 1998, Biopure faced the monumental decision of whether to begin selling Oxyglobin, a blood substitute, to the veterinary market or to wait until Hemoglobin, a blood substitute for the human market, became available for sale. Biopure’s problem was simple: should the company launch Oxyglobin before Hemoglobin is FDA-approved
Words: 1385 - Pages: 6
MKTG 510 Jason Biopure Case Recommendations 6/4/13 To: Carl Rausch, President and CEO of Biopure Corporation From: Jason RE: Biopure Product Release Analysis Date: 6/4/13 Dear Mr. Rausch, The contents of this letter will provide you the information and analysis you will require in order to make an effective decision on the timely release of your Biopure products (Oxyglobin and Hemopure). Reccomendation Based on the analysis conducted by our firm, we are recommending you proceed
Words: 438 - Pages: 2
outweighs this concern. Here are the reasons why Oxyglobin should be released soon in the market: * As FDA approval takes time, being the first player in the market will give us an edge over the others and we will get an opportunity to establish Biopure. The possibility of success of Oxyglobin will become a platform for Hemopure to use the brand image already built. * The competitors Baxter Internationals and Northfield Laboratories are expected to release their products for human blood substitute
Words: 738 - Pages: 3
The Biopure Corporation developed two new “blood substitutes”: Oxyglobin (targeted the veterinary market) and Hemopure (targeted the human market). Oxyglobin was ready for the market, but Hemopure needed two more years to launch. Therefore, Carl Rausch, the CEO of Biopure, had to decide whether or not Biopure should launch Oxyglobin first or wait for Hemopure. Oxyglobin and Hemopure were almost identical in physical properties and appearance. However, the veterinary market was smaller than the human
Words: 379 - Pages: 2
financial cases that involve what can be best described as foreign or international elements. In such cases, court must decide whether it has the jurisdiction under the Family Law Act 1975 to make a decision on such cases. In the event that it is determined that the court is invested with the jurisdiction to determine the case, the court has to consider whether there is a system of law in foreign country that also has the jurisdiction to handle the case. As it was addressed in the case Attorney General
Words: 659 - Pages: 3
